礼来(LLY)斥资最多25亿美元收购一种实验性的癌症口服疗法

金吾财讯
14 Jan

金吾财讯 | 有报道指,礼来(LLY)斥资最多25亿美元,收购一种实验性的癌症口服疗法。这家公司的实验性口服疗法目前正在早期试验阶段,主要用于治疗乳癌及其他晚期实体肿瘤。交易作价会随着试验进程,而分多期支付。另外,报道引述礼来行政总裁(CEO)戴文睿表示,公司的实验性减肥药最快可于明年初获批。这只药较目前的注射形式更方便、生产亦更容易。礼来曾透露,有关药物在中期试验,试用者减重14.7%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10